RPRX Articles, Royalty Pharma plc - From 05/02/24

Amgen Inc. (NASDAQ:AMGN) reported first-quarter financial results after the closing bell Thursday. Here's a look at the highlights. The Detai...

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2024 financi...

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend f...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD C...

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend...

2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range Announced transactions of $13 bill...

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it is scheduled to participate in a fireside c...

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend fo...

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice P...

• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and...